Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China | ||
By: Nasdaq / GlobeNewswire - 16 Sep 2019 | Back to overview list |
|
Helsinn and Mundipharma China Pharmaceutical jointly announce NMPA’s approval of the oral formulation of Akynzeo® in China Lugano, Switzerland, and Beijing, China, September 16, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, today jointly announce that the National Medical Products Administration (NMPA) has approved the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting (CINV) in China. Under the terms of the agreement, Mundipharma China Pharmaceutical has exclusive marketing, promotion and sale rights for the oral formulation of Akynzeo® in China. Helsinn will be responsible for supplying the drug to Mundipharma and co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities. Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: “Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo® that targets two CINV critical pathways in a single dose will help patients and their families also in China “We are also very pleased to be working in partnership with Mundipharma Pharmaceutical. Their expert knowledge and network in China will be invaluable as we begin to market Akynzeo® in this strategically important region.” Peter Wang, CEO of Mundipharma Pharmaceutical Greater China commented: “Today’s announcement will be welcomed by Chinese cancer patients, who are undergoing chemotherapy while having to fight against CINV, as well as caregivers. It is also an important extension of Mundipharma China’s portfolio. We look forward to continuing to partner with Helsinn to bring more high-quality cancer supportive care products to millions of Chinese cancer patients in the near future, in line with our vision of ‘Bring more to life.” About Akynzeo® in China About the Helsinn Group To learn more about Helsinn Group please visit www.helsinn.com About Mundipharma China Pharmaceutical Mundipharma China Pharmaceutical was established in the year of 1993 and has been dedicated to the organic growth of the pain segment in China for decades. “Bring More to Life” is our aspiration; caring for lives and serving the society is our social responsibilities. Innovation, patient-centric, and entrepreneurship are in our DNAs. In the future, Mundipharma China will continue to explore in pain management field and expand its business into new fields, including CINV, transplantation immunology, oncology, respiratory, and etc. We’ll make unremitting efforts to providing innovative products and fulfilling our social responsibilities, ultimately to realize our vision of “Bring More to Life”. For more information: Helsinn Group Media Contact Paola Bonvicini Group Head of Communication Lugano, Switzerland Tel: +41 (0) 91 985 21 21 For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo Mundipharma China Pharmaceutical Contact: Kylie Gao, PR Director Beijing, China Tel: +86(10) 6563 6785 Email: kylie.gao@mundipharma.com.cn PMAP:CN-NA-0764-0919 |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |